EPISODE · Oct 14, 2025 · 7 MIN
The Next Safety Gap; How Compounded GLP-1s Expose the Limits of Oversight
from Microdosing · host Paul Schrimpf
As demand for GLP-1 drugs like Ozempic and Wegovy soars, a parallel market for compounded versions has emerged — one that’s largely unregulated and increasingly risky. This episode examines how gaps in oversight, aggressive marketing, and blurred lines between compounding and manufacturing expose patients to safety concerns and strain the health system. We explore why compounded GLP-1s are more than a niche issue, highlighting how they fit a recurring pattern where regulation lags behind fast-moving markets.
What this episode covers
As demand for GLP-1 drugs like Ozempic and Wegovy soars, a parallel market for compounded versions has emerged — one that’s largely unregulated and increasingly risky. This episode examines how gaps in oversight, aggressive marketing, and blurred lines between compounding and manufacturing expose patients to safety concerns and strain the health system. We explore why compounded GLP-1s are more than a niche issue, highlighting how they fit a recurring pattern where regulation lags behind fast-moving markets.
NOW PLAYING
The Next Safety Gap; How Compounded GLP-1s Expose the Limits of Oversight
No transcript for this episode yet
Similar Episodes
Jun 10, 2026 ·121m
Jun 5, 2026 ·42m
May 20, 2026 ·58m